A modified scoring of the NCCN‐IPI is more accurate in the elderly and is improved by albumin and β2‐microglobulin

Summary The International Prognostic Index (IPI) has been used for decades in diffuse large B‐cell lymphoma (DLBCL). A retrospective cancer registry analysis in North America showed significantly improved results when an enhanced IPI, the National Comprehensive Cancer Network (NCCN)‐IPI was applied....

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:British journal of haematology Ročník 168; číslo 2; s. 239 - 245
Hlavní autori: Melchardt, Thomas, Troppan, Katharina, Weiss, Lukas, Hufnagl, Clemens, Neureiter, Daniel, Tränkenschuh, Wolfgang, Hopfinger, Georg, Magnes, Teresa, Deutsch, Alexander, Neumeister, Peter, Hackl, Hubert, Greil, Richard, Pichler, Martin, Egle, Alexander
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: England 01.01.2015
Predmet:
Adult
Age Factors
Aged
Aged, 80 and over
albumin
Albumins - analysis
beta 2-Microglobulin - blood
diffuse large B cell lymphoma
Disease-Free Survival
elderly
Female
Humans
Lymphoma, Large B-Cell, Diffuse - blood
Magnetic Resonance Imaging - methods
Male
Middle Aged
NCCN‐IPI
Prognosis
Retrospective Studies
Survival Analysis
Young Adult
β2‐microglobulin
diffuse large B cell lymphoma
elderly
β2-microglobulin
NCCN-IPI
albumin
ISSN:0007-1048, 1365-2141, 1365-2141
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Summary The International Prognostic Index (IPI) has been used for decades in diffuse large B‐cell lymphoma (DLBCL). A retrospective cancer registry analysis in North America showed significantly improved results when an enhanced IPI, the National Comprehensive Cancer Network (NCCN)‐IPI was applied. This novel score puts more weight on age and high levels of lactate dehydrogenase (LDH). Nevertheless, it remains unclear if these results can be extrapolated to the general population. This retrospective bi‐centre analysis included 499 unselected DLBCL patients who were treated with rituximab and anthracycline‐based chemoimmunotherapy between 2004 and 2013. In our cohort, the NCCN‐IPI was more accurate in identifying patients at low or high risk, despite older age, and more patients with increased LDH. Nevertheless, a modified scoring of the risk factors was required to more accurately identify elderly patients with a very favourable diagnosis, suggesting an impaired value of the original NCCN‐IPI in the elderly. Serum β2‐microglobulin and albumin were retained as independent prognostic factors for survival in a multivariate analysis. Our data confirm, for the first time, the superior prognostic power of the NCCN‐IPI in an unselected, middle‐European cohort. We furthermore propose a modified NCCN‐IPI for more accurate prognostication in the elderly. Albumin and β2‐microglobulin levels are likely to add significant information to the NCCN‐IPI.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0007-1048
1365-2141
1365-2141
DOI:10.1111/bjh.13116